Login / Signup

Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement.

Ayushi ChauhanRoss ApostolovDaniel R Van LangenbergMayur Garg
Published in: Internal medicine journal (2021)
Faecal microbiota transplantation (FMT) is reportedly effective and safe for the management of recurrent or refractory Clostridioides difficile infection (CDI), yet real-world data of outcomes of FMT in Australia are limited. In this series, FMT safely resulted in resolution of CDI in 19 patients with reduced healthcare utilisation after 25 FMT, but one patient was diagnosed with an anti-nuclear antibody-positive constitutional illness and Hashimoto thyroiditis following FMT. Further prospective evaluation of the utility of FMT earlier in CDI treatment algorithms to minimise cost and morbidity, and recipient follow up for immune-mediated conditions, is required.
Keyphrases
  • clostridium difficile
  • healthcare
  • cell therapy
  • type diabetes
  • stem cells
  • electronic health record
  • mesenchymal stem cells
  • adipose tissue
  • single molecule
  • bone marrow
  • data analysis